About this Research Topic
Cardiovascular diseases, particularly arterial hypertension, are still a dominant cause of mortality worldwide. In spite of significant progress in understanding the pathogenesis of cardiovascular diseases, it is often not possible to select optimum pharmacological therapy, which should be chosen based on factors such as sex, age, coexistence of other diseases, and application of other pharmacological therapies for an individual patient. Currently, primary efforts of modern research is focused in two main areas. First, is better recognition of mechanisms of disease which are responsible for the adjustment of the function of the cardiovascular system to altered hemodynamic conditions in individual patients. Second, the comprehensive elucidation of the mechanisms of action of cardiovascular pharmaceuticals in patients suffering from underlying diseases such that optimal treatment requires drugs targeting more than one mode of action. Discovery of the renin-angiotensin-aldosterone system was a milestone for cardiovascular pharmacology. However, there are still many unsolved problems regarding efficacy of pharmaceuticals interfering with the actions of particular components of this system in arterial hypertension and heart failure.
Since the outstanding discovery by John Laragh and his group of the association between renin secretion and development of hypertension, worldwide research has shown that renin is part of the complex renin-angiotensin-aldosterone system (RAAS), which is involved in the regulation of multiple functions of the body and interacts with several signaling pathways associated with cardiovascular regulation in a manner adjusted to specific physiological and pathological conditions. The purpose of this Research Topic is to draw more attention to specific roles played by the components of RAAS to impact multiple cardiovascular functions under different pathological conditions. We also wish to emphasize the necessity of individualization of pharmacological therapies targeting RAAS, with regard to an individual patient’s age, sex, coexistent diseases and use of other pharmacological therapies.
This Research Topic will act as a reliable and impactful source of knowledge on current trends in the field of treatment of cardiovascular diseases relating to the RAAS. There is a focus on RAAS because of the advancements in understanding multiple functions of this system, as well as continual progress in the synthesis of promising pharmaceutical compounds to correct inappropriate functions of specific components of this system.
We welcome Reviews, Original Research, Mini Reviews, and Opinion article types. We expect submissions relating, but not limited to, the following themes:
• Central and systemic regulation of renin-angiotensin-aldosterone systems with emphasize on the role of the autonomic nervous system;
• Role of central and systemic renin-angiotensin-aldosterone systems in cardiovascular pathology;
• John Laragh’s legacy for the current understanding of the renin-angiotensin-aldosterone system;
• Renin-angiotensin-aldosterone system involvement in renovascular hypertension;
• High renin and resistant hypertension and the role of renin-angiotensin- aldosterone system;
• New pharmacological compounds interfering with the renin-angiotensin-aldosterone system ;
• Clinical usefulness of renin-angiotensin-aldosterone system inhibitors in cardiovascular pathology;
• Links between infections and the renin-angiotensin-aldosterone system with impact on COVID-19.
Keywords: aldosterone receptors, angiotensin receptors, cardiovascular reflexes, hypertension, heart failure
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.